Literature DB >> 26058074

The Next Wave of EGFR Tyrosine Kinase Inhibitors Enter the Clinic.

Katerina Politi1, Deborah Ayeni2, Thomas Lynch3.   

Abstract

The T790M mutation in EGFR accounts for approximately half of all lung cancer cases with acquired resistance to the current clinical EGFR tyrosine kinase inhibitors. In tyrosine kinase inhibitor-resistant lung tumors, rociletinib and AZD9291 are highly active when T790M is present and modestly active when T790M is absent.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26058074     DOI： 10.1016/j.ccell.2015.05.012

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


  27 in total

1.  Superior Efficacy and Selectivity of Novel Small-Molecule Kinase Inhibitors of T790M-Mutant EGFR in Preclinical Models of Lung Cancer.

Authors:  Jin Kyung Rho; In Yong Lee; Yun Jung Choi; Chang-Min Choi; Jae-Young Hur; Jong Sung Koh; Jaekyoo Lee; Byung-Chul Suh; Ho-Juhn Song; Paresh Salgaonkar; Jungmi Lee; Jaesang Lee; Dong Sik Jung; Sang-Yeob Kim; Dong-Cheol Woo; In-Jeoung Baek; Joo-Yong Lee; Chang Hoon Ha; Young Hoon Sung; Jeong Kon Kim; Woo Sung Kim; Joon Seon Song; Cheol Hyeon Kim; Trever G Bivona; Jae Cheol Lee
Journal:  Cancer Res       Date:  2017-01-12       Impact factor: 12.701

2.  The inhibition of epidermal growth factor receptor signaling by hexagonal selenium nanoparticles modified by SiRNA.

Authors:  L Kamrani Moghaddam; S Ramezani Paschepari; M A Zaimy; A Abdalaian; A Jebali
Journal:  Cancer Gene Ther       Date:  2016-09-09       Impact factor: 5.987

3.  [AZD9291 suppresses proliferation and migration of nasopharyngeal carcinoma cells by inhibiting the PI3K-AKT-mTOR pathway].

Authors:  H Zhang; J Pang; Y Zhang; Y Ma; F Fan; H Liu
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2022-09-20

4.  Discovery of a Potent and Mutant-Selective EGFR Inhibitor that Overcomes T790M-Mediated Resistance in Lung Cancer.

Authors:  Dong Ha Kim; Yun Jung Choi; Seon Ye Kim; Jung-Eun Lee; Ki Jung Sung; Young Hoon Sung; Woo Sung Kim; Sung-Eun Kim; Hyung Chul Ryu; Jae Sun Kim; Lu Guangying; Chang-Min Choi; Jin Kyung Rho; Jae Cheol Lee
Journal:  Target Oncol       Date:  2018-06       Impact factor: 4.493

5.  Oncogenic EGFR Represses the TET1 DNA Demethylase to Induce Silencing of Tumor Suppressors in Cancer Cells.

Authors:  Matteo Forloni; Romi Gupta; Arvindhan Nagarajan; Li-Sha Sun; Yuying Dong; Valentina Pirazzoli; Maria Toki; Anna Wurtz; Mary Ann Melnick; Susumu Kobayashi; Robert J Homer; David L Rimm; Scott J Gettinger; Katerina Politi; Shaillay Kumar Dogra; Narendra Wajapeyee
Journal:  Cell Rep       Date:  2016-06-23       Impact factor: 9.423

Review 6.  Treatment-Induced Mutagenesis and Selective Pressures Sculpt Cancer Evolution.

Authors:  Subramanian Venkatesan; Charles Swanton; Barry S Taylor; Joseph F Costello
Journal:  Cold Spring Harb Perspect Med       Date:  2017-08-01       Impact factor: 6.915

7.  An Open Library of Human Kinase Domain Constructs for Automated Bacterial Expression.

Authors:  Steven K Albanese; Daniel L Parton; Mehtap Işık; Lucelenie Rodríguez-Laureano; Sonya M Hanson; Julie M Behr; Scott Gradia; Chris Jeans; Nicholas M Levinson; Markus A Seeliger; John D Chodera
Journal:  Biochemistry       Date:  2018-07-26       Impact factor: 3.162

8.  HOTAIR, a long noncoding RNA, is a marker of abnormal cell cycle regulation in lung cancer.

Authors:  Minghui Liu; Hongyi Zhang; Ying Li; Rui Wang; Yongwen Li; Hongbing Zhang; Dian Ren; Hongyu Liu; Chunsheng Kang; Jun Chen
Journal:  Cancer Sci       Date:  2018-09       Impact factor: 6.716

Review 9.  A Rational Approach to Target the Epidermal Growth Factor Receptor in Glioblastoma.

Authors:  Madan M Kwatra
Journal:  Curr Cancer Drug Targets       Date:  2017       Impact factor: 3.428

10.  [Cell Cycle Checkpoint Kinase and Drug Resistance of Lung Cancer].

Authors:  Zhiyin Ke; Ailing Liang; Yongjun Liu
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2021-04-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.